Pipeline


ImmunoBiochem pipeline consists of antibody-drug conjugates (ADCs) for oncology. ADCs comprise a novel class of potentiated biological therapeutics. ADCs combine the targeting capabilities of monoclonal antibodies with cytotoxic properties of small molecule cancer drugs to selectively and specifically destroy cancer cells while minimizing damage to normal tissues. ADCs comprise an antibody component linked to a cytotoxic molecule via a stable linker that is uniquely engineered to deliver and release the cytotoxic payload in cancer cells.
ImmunoBiochem's lead ADC candidates, IMB-201 and IMB-202, are based on fully-human antibodies and are in development for a number of solid malignancies.

IMB-201
IMB-201 is a novel antibody-drug conjugate (ADC) that is targeted at an undisclosed tumor antigen in the secretome of cancer cells. IMB-201 is based on ImmunoBiochem's proprietary technology platform that enables it to target an antigen that is normally intracellular and uniquely differentiates it from all other ADCs currently in development. IMB-201 is based on a stable linkage of the cytotoxic payload and is currently at the preclinical stage of development.

IMB-202
IMB-202 is a novel antibody-drug conjugate (ADC) that is targeted at an undisclosed tumor antigen in the secretome of cancer cells. IMB-202 is based on ImmunoBiochem's proprietary technology platform that enables it to target an antigen that is normally intracellular and uniquely differentiates it from all other ADCs currently in development. IMB-202 is based on a cleavable linkage of the cytotoxic payload and is currently at the preclinical stage of development.